The Complex Genetics of Epilepsy: New Insights into a Common Neurological Disorder
Epilepsy, a chronic neurological disorder affecting over 50 million people worldwide, is far more genetically complex than previously understood. Recent research, spearheaded by Dr. Olav B. Smeland of the Centre for Precision Psychiatry at Oslo University Hospital and the University of Oslo, is unraveling the intricate genetic architecture underlying these seizure disorders. This review synthesizes findings from genome-wide association studies, whole-exome sequencing, and advanced statistical modeling to provide a detailed portrait of epilepsy’s genetic landscape.
Understanding Epilepsy’s Complexity
Epilepsy isn’t a single disease but a spectrum of seizure disorders. Determining the factors that contribute to the development of epilepsy, its specific subtypes, and treatment response has been a long-standing challenge. Genetic research has historically followed two paths: studying severe, monogenic epilepsies (caused by mutations in a single gene) and investigating common epilepsies, which are influenced by multiple genes.
From Twin Studies to Modern Molecular Methods
Early research relied on twin studies, demonstrating higher concordance rates for epilepsy in monozygotic (identical) twins compared to dizygotic (fraternal) twins. A large study of over 47,000 twin pairs showed a 28% concordance rate in monozygotic twins versus 7%. However, concordance rates varied significantly between epilepsy subtypes. Genetic generalized epilepsy exhibited a 77% concordance in monozygotic twins, whereas focal epilepsy showed only 40%.
Modern molecular methods quantify heritability through SNP-heritability, estimating the proportion of phenotypic variation attributable to common genetic variants. Genetic generalized epilepsy demonstrates approximately three times higher SNP-heritability than focal epilepsy. Subtypes like juvenile myoclonic epilepsy and childhood absence epilepsy reveal even higher heritability estimates, highlighting the importance of precise diagnosis in genetic research.
The Role of Rare Genetic Variants
Rare genetic variants, those with a minor allele frequency below 1%, also contribute to epilepsy risk, though they account for a minority of cases. A study of over 13,400 epilepsy cases revealed an increased burden of copy number variants across all common epilepsy types, with genetic generalized epilepsy showing the highest burden. Deletions at the 15q13.3 locus were identified as a strong risk factor for genetic generalized epilepsy, with an odds ratio of 36.04.
Whole-exome sequencing studies have identified protein-truncating variants in genes encoding components of the GATOR1 complex, a negative regulator of the mTORC1 pathway, as contributors to non-acquired focal epilepsy risk. Notably, these findings converge with those from common variant analyses, with genes like DEPDC5, NPRL3, SCN1A, and SCN8A appearing in both types of studies, suggesting shared biological pathways related to ion channel function and synaptic excitability.
Genome-Wide Association Studies Reveal Genetic Loci
The largest genome-wide association study (GWAS) of common epilepsies to date, involving nearly 30,000 cases and 52,538 controls, identified 26 genome-wide significant loci. However, the distribution was uneven: 22 loci were associated with genetic generalized epilepsy, while focal epilepsy, despite having more cases (over 16,000), yielded no genome-wide significant associations. This asymmetry suggests fundamental differences in the genetic architecture between subtypes.
Genetic Overlap with Psychiatric Disorders
Research highlights significant genetic pleiotropy, where genetic variants influence multiple traits. The genetic correlation between focal epilepsy and genetic generalized epilepsy is 0.61. Both forms of epilepsy show moderate negative genetic correlations with cognitive ability. Variants associated with genetic generalized epilepsy are also linked to major psychiatric disorders, including schizophrenia, major depression, bipolar disorder, and anxiety.
“The extensive genetic overlap between epilepsy and psychiatric disorders provides a molecular explanation for what clinicians have long observed at the bedside,” said Naz Karadag, a researcher at the Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo. “Understanding these shared genetic foundations may eventually help identify epilepsy patients at elevated risk for psychiatric comorbidities.”
Polygenic Risk Scores and Future Directions
Polygenic risk scores, which estimate an individual’s genetic predisposition to a disease, show promise in risk stratification, particularly after a first unprovoked seizure. However, current scores are not accurate enough for population screening and are primarily based on studies of European ancestry, limiting their generalizability. Dr. Smeland cautions against using current scores for routine clinical decision-making until ancestral diversity is broadened in study populations.
Future research will focus on integrating genetics with other data modalities, including clinical variables, cognitive assessments, other omics data, electronic health records, neuroimaging, and data from wearable sensors. Large biobanks, such as the UK Biobank and the All of Us Research Program, will be crucial platforms for these integrated analyses.
The Path Forward
The genetic architecture of common epilepsies offers a relatively favorable ratio of heritability to polygenicity, suggesting that larger, more diverse studies could capture a significant portion of the common genetic variance. The field is still in its early stages, but the potential for clinical translation is growing. A coordinated effort to increase sample sizes, improve phenotypic characterization, and integrate diverse data types will be essential to unlock the full potential of epilepsy genetics.